{"success":true,"data":{"pressRelease":{"id":"150769","rtpr_id":"nGNX8mnq8K-20260923","ticker":"CMND","exchange":"NASDAQ","all_tickers":["CMND","NTLX"],"title":"Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations","author":"Globe Newswire","published_at":"2026-09-23T11:57:00.092Z","article_body":"The covered applications address potential therapeutic uses across a range of\nindications, including mental health disorders, such as depression and PTSD as\nwell as substance use disorders\n\nVancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc.\n(Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company\nadvancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable\ntreatment  of neuropsychiatric, metabolic, and addiction disorders including\nAlcohol Use Disorder (“AUD”), today announced the publication in the\nUnited States of three patent applications covering novel proprietary\ncombinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine\nwith N-acylethanolamines, such as palmitoylethanolamide (“PEA”). The\ncovered applications address potential therapeutic uses across a range of\nindications, including mental health disorders, such as depression,\npost-traumatic stress disorder (“PTSD”), pain and substance use disorders.\n\nThe publications expand the intellectual property generated through\nClearmind’s ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX),\nunder which NeuroThera’s PEA technology is integrated into Clearmind’s\npsychedelic-derived therapeutic programs. The collaboration has resulted in a\ngrowing portfolio of patent applications covering combinations of PEA with\npsychedelic and psychoactive compounds. Clearmind previously announced U.S.\npublication of a patent application covering the combination of MDMA and\nN-acylethanolamines for potential treatment of PTSD, anxiety and eating\ndisorders.\n\n“The publication of these patents come at a significant time as clinical and\nregulatory interest in LSD, ketamine and ibogaine continues to receive growing\nrecognition and support for their therapeutic potential. Clearmind believes\nits combination approach may offer the potential for an effective and safer\ntreatment paradigm, aiming to achieve therapeutic benefits at lower doses\nwhile preserving efficacy. By reducing the dose required to achieve the\nintended pharmacological effect, this approach may support improved\ntolerability while maintaining therapeutic potential.,” said Adi\nZuloff‑Shani, Ph.D., Chief Executive Officer of Clearmind.\n\nAbout Clearmind Medicine Inc.\n\nClearmind is a clinical-stage neuroplastogens pharmaceutical biotech company\nfocused on the discovery and development of non-hallucinogenic, second\ngeneration, neuroplastogen-derived therapeutics to solve widespread and\nunderserved health problems, including alcohol use disorder. Its primary\nobjective is to research and develop psychedelic-based compounds and attempt\nto commercialize them as regulated medicines, foods, or supplements.\n\nThe Company’s intellectual portfolio currently consists of nineteen patent\nfamilies, including 32 granted patents. The Company intends to seek additional\npatents for its compounds whenever warranted and will remain opportunistic\nregarding the acquisition of additional intellectual property to build its\nportfolio.\n\nShares of Clearmind are listed for trading on Nasdaq under the symbol \"CMND.\"\n\nFor further information, visit: https://www.clearmindmedicine.com or\ncontact:\n\nInvestor Relations\ninvest@clearmindmedicine.com\nwww.Clearmindmedicine.com\n\nForward-Looking Statements:\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act and other securities\nlaws. Words such as “expects,” “anticipates,” “intends,”\n“plans,” “believes,” “seeks,” “estimates” and similar\nexpressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the potential therapeutic applications of the\ncombinations covered by the published patent applications; the potential\nbenefits, advantages and characteristics of such combinations, including the\npossibility of achieving therapeutic benefits at lower doses and supporting\ntolerability; the Company's intellectual property strategy and patent\nportfolio; the expected benefits of its collaboration with NeuroThera Labs\nInc.; and the development, advancement and commercial potential of the\nCompany's product candidates and technologies. The Company cannot assure that\nany patent will issue as a result of a pending patent application or, if\nissued, whether it will issue in a form that will be advantageous to the\nCompany. Forward-looking statements are not historical facts, and are based\nupon management’s current expectations, beliefs and projections, many of\nwhich, by their nature, are inherently uncertain. Such expectations, beliefs\nand projections are expressed in good faith. However, there can be no\nassurance that management’s expectations, beliefs and projections will be\nachieved, and actual results may differ materially from what is expressed in\nor indicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission (“SEC”),\nincluding, but not limited to, the risks detailed in the Company’s annual\nreport on Form 20-F for the fiscal year ended October 31, 2025 and subsequent\nfilings with the SEC. Forward-looking statements speak only as of the date the\nstatements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Clearmind is not\nresponsible for the contents of third-party websites.\n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bd17cbf4-8124-4f86-8a4c-1fafbb6785af)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8mnq8K-20260923","title":"Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations","author":"Globe Newswire","ticker":"CMND","created":"2026-09-23T11:57:00.092Z","tickers":["CMND","NTLX"],"exchange":"NASDAQ","article_body":"The covered applications address potential therapeutic uses across a range of\nindications, including mental health disorders, such as depression and PTSD as\nwell as substance use disorders\n\nVancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc.\n(Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company\nadvancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable\ntreatment  of neuropsychiatric, metabolic, and addiction disorders including\nAlcohol Use Disorder (“AUD”), today announced the publication in the\nUnited States of three patent applications covering novel proprietary\ncombinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine\nwith N-acylethanolamines, such as palmitoylethanolamide (“PEA”). The\ncovered applications address potential therapeutic uses across a range of\nindications, including mental health disorders, such as depression,\npost-traumatic stress disorder (“PTSD”), pain and substance use disorders.\n\nThe publications expand the intellectual property generated through\nClearmind’s ongoing collaboration with NeuroThera Labs Inc. (TSXV: NTLX),\nunder which NeuroThera’s PEA technology is integrated into Clearmind’s\npsychedelic-derived therapeutic programs. The collaboration has resulted in a\ngrowing portfolio of patent applications covering combinations of PEA with\npsychedelic and psychoactive compounds. Clearmind previously announced U.S.\npublication of a patent application covering the combination of MDMA and\nN-acylethanolamines for potential treatment of PTSD, anxiety and eating\ndisorders.\n\n“The publication of these patents come at a significant time as clinical and\nregulatory interest in LSD, ketamine and ibogaine continues to receive growing\nrecognition and support for their therapeutic potential. Clearmind believes\nits combination approach may offer the potential for an effective and safer\ntreatment paradigm, aiming to achieve therapeutic benefits at lower doses\nwhile preserving efficacy. By reducing the dose required to achieve the\nintended pharmacological effect, this approach may support improved\ntolerability while maintaining therapeutic potential.,” said Adi\nZuloff‑Shani, Ph.D., Chief Executive Officer of Clearmind.\n\nAbout Clearmind Medicine Inc.\n\nClearmind is a clinical-stage neuroplastogens pharmaceutical biotech company\nfocused on the discovery and development of non-hallucinogenic, second\ngeneration, neuroplastogen-derived therapeutics to solve widespread and\nunderserved health problems, including alcohol use disorder. Its primary\nobjective is to research and develop psychedelic-based compounds and attempt\nto commercialize them as regulated medicines, foods, or supplements.\n\nThe Company’s intellectual portfolio currently consists of nineteen patent\nfamilies, including 32 granted patents. The Company intends to seek additional\npatents for its compounds whenever warranted and will remain opportunistic\nregarding the acquisition of additional intellectual property to build its\nportfolio.\n\nShares of Clearmind are listed for trading on Nasdaq under the symbol \"CMND.\"\n\nFor further information, visit: https://www.clearmindmedicine.com or\ncontact:\n\nInvestor Relations\ninvest@clearmindmedicine.com\nwww.Clearmindmedicine.com\n\nForward-Looking Statements:\n\nThis press release contains “forward-looking statements” within the\nmeaning of the Private Securities Litigation Reform Act and other securities\nlaws. Words such as “expects,” “anticipates,” “intends,”\n“plans,” “believes,” “seeks,” “estimates” and similar\nexpressions or variations of such words are intended to identify\nforward-looking statements. For example, the Company is using forward-looking\nstatements when it discusses the potential therapeutic applications of the\ncombinations covered by the published patent applications; the potential\nbenefits, advantages and characteristics of such combinations, including the\npossibility of achieving therapeutic benefits at lower doses and supporting\ntolerability; the Company's intellectual property strategy and patent\nportfolio; the expected benefits of its collaboration with NeuroThera Labs\nInc.; and the development, advancement and commercial potential of the\nCompany's product candidates and technologies. The Company cannot assure that\nany patent will issue as a result of a pending patent application or, if\nissued, whether it will issue in a form that will be advantageous to the\nCompany. Forward-looking statements are not historical facts, and are based\nupon management’s current expectations, beliefs and projections, many of\nwhich, by their nature, are inherently uncertain. Such expectations, beliefs\nand projections are expressed in good faith. However, there can be no\nassurance that management’s expectations, beliefs and projections will be\nachieved, and actual results may differ materially from what is expressed in\nor indicated by the forward-looking statements. Forward-looking statements are\nsubject to risks and uncertainties that could cause actual performance or\nresults to differ materially from those expressed in the forward-looking\nstatements. For a more detailed description of the risks and uncertainties\naffecting the Company, reference is made to the Company’s reports filed from\ntime to time with the Securities and Exchange Commission (“SEC”),\nincluding, but not limited to, the risks detailed in the Company’s annual\nreport on Form 20-F for the fiscal year ended October 31, 2025 and subsequent\nfilings with the SEC. Forward-looking statements speak only as of the date the\nstatements are made. The Company assumes no obligation to update\nforward-looking statements to reflect actual results, subsequent events or\ncircumstances, changes in assumptions or changes in other factors affecting\nforward-looking information except to the extent required by applicable\nsecurities laws. If the Company does update one or more forward-looking\nstatements, no inference should be drawn that the Company will make additional\nupdates with respect thereto or with respect to other forward-looking\nstatements. References and links to websites have been provided as a\nconvenience, and the information contained on such websites is not\nincorporated by reference into this press release. Clearmind is not\nresponsible for the contents of third-party websites.\n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bd17cbf4-8124-4f86-8a4c-1fafbb6785af)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-23T11:57:00.140000643Z","server_sent_at_ms":1790164620140},"received_at":"2026-09-23T11:57:00.195Z","source_url":null},"analysis":{"id":"139572","press_release_id":"150769","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["patent applications published, not granted -- no assurance any will issue","early-stage clinical company with no commercial revenue; preclinical therapeutic potential only"],"eventType":"other","narrative":"Clearmind Medicine announced U.S. publication of three patent applications covering proprietary combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as PEA, targeting depression, PTSD, pain and substance use disorders.\n\nThe IP stems from Clearmind's ongoing collaboration with NeuroThera Labs (TSXV: NTLX), and follows an earlier published application covering MDMA plus N-acylethanolamines.\n\nThe company's portfolio now spans nineteen patent families with 32 granted patents, though the newly published applications carry no assurance of issuance.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Incremental IP build-out for Clearmind's psychedelic-combination platform -- noteworthy for long-term pipeline, not a near-term catalyst."},"keyFigures":{"customDimensions":{"granted_patents":32,"patent_applications_published":3}},"quotedText":"The publication of these patents come at a significant time as clinical and regulatory interest in LSD, ketamine and ibogaine continues to receive growing recognition and support for their therapeutic potential.","namedEntities":{"people":[{"name":"Adi Zuloff-Shani, Ph.D.","role":"CEO"}],"products":["LSD-PEA combination","ketamine-PEA combination","ibogaine-PEA combination","MDMA-N-acylethanolamines combination","palmitoylethanolamide (PEA)"],"companies":[{"name":"Clearmind Medicine Inc.","ticker":"CMND","relationship":"filer"},{"name":"NeuroThera Labs Inc.","ticker":"NTLX","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Publication of three U.S. patent applications is an incremental IP milestone, not a granted patent or clinical/regulatory event. It strengthens the portfolio but has no direct revenue or clinical-trial impact yet."},"tickerRelevance":{"others":[{"ticker":"NTLX","relevance":"partner"}],"primary":"CMND"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"patent-application-publication","sectorWeight":"speculative-biotech","issuerAuthored":true}},"event_type":"other","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"Clearmind Medicine announced U.S. publication of three patent applications covering proprietary combinations of LSD, ketamine and ibogaine with N-acylethanolamines such as PEA, targeting depression, PTSD, pain and substance use disorders.\n\nThe IP stems from Clearmind's ongoing collaboration with NeuroThera Labs (TSXV: NTLX), and follows an earlier published application covering MDMA plus N-acylethanolamines.\n\nThe company's portfolio now spans nineteen patent families with 32 granted patents, though the newly published applications carry no assurance of issuance.","key_figures":{"customDimensions":{"granted_patents":32,"patent_applications_published":3}},"named_entities":{"people":[{"name":"Adi Zuloff-Shani, Ph.D.","role":"CEO"}],"products":["LSD-PEA combination","ketamine-PEA combination","ibogaine-PEA combination","MDMA-N-acylethanolamines combination","palmitoylethanolamide (PEA)"],"companies":[{"name":"Clearmind Medicine Inc.","ticker":"CMND","relationship":"filer"},{"name":"NeuroThera Labs Inc.","ticker":"NTLX","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-23T11:57:05.990Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"patent-application-publication","sectorWeight":"speculative-biotech","issuerAuthored":true}},"durationMs":5778,"modelName":"glm-5.3-flashx"}}